Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

PURPOSE: Both gemcitabine (GEM) and fluoropyrimidines are valuable treatment for advanced pancreatic cancer. This open-label study was designed to compare the overall survival (OS) of patients randomly assigned to GEM alone or GEM plus capecitabine (GEM-CAP). PATIENTS AND METHODS: Patients with previously untreated histologically or cytologically proven locally advanced or metastatic carcinoma of the pancreas with a performance status

• CR
  Cancer Research Institute
• NC
  National Cancer Research Institute
• NB
  NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
• NI
  National Institute for Health and Care Research
• SA
  Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung